RT Journal Article
SR Electronic
T1 The new oral anticoagulants: Reasonable alternatives to warfarin
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 847
OP 854
DO 10.3949/ccjm.82a.14052
VO 82
IS 12
A1 Roca, Bernardino
A1 Roca, Manuel
YR 2015
UL http://www.ccjm.org/content/82/12/847.abstract
AB Dabigatran (a direct thrombin inhibitor) and rivaroxaban, apixaban, and edoxaban (direct activated factor X inhibitors) are increasingly being used in clinical practice. Compared with vitamin K antagonists, they are more convenient, do not require laboratory monitoring, have limited drug and food interactions, and have fixed dosages suitable for most patients. But the shortcomings of these agents can jeopardize their efficacy and increase the risk of bleeding. Their future role in preventing and treating thromboembolic disease will depend on building clinical experience, but current evidence indicates that they are reasonable alternatives to vitamin K antagonists.